COHANCE LIFESCIENCES LTD (COHANCE) financials

COHANCE LIFESCIENCES LTD (COHANCE) NSE/BSE financials on Fincrux: quarterly results, profit and loss, cash flow, balance sheet, ratios, and shareholding.

Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules.[1][2]

Market Cap: ₹17,511Cr.
Current Price: ₹458
Stock P/E: 91.6
ROE: 5.70%
ROCE: 7.91%
Book Value: ₹117
Dividend Yield: 0.00%
52W High / Low: ₹918/267

In Jun 2026, COHANCE LIFESCIENCES LTD (COHANCE) reported sales ₹359.89 Cr and net profit ₹1.41 Cr.

Annual TTM: sales ₹1,907 Cr, net profit ₹178 Cr.

Shareholding: Promoters 57.48% (Sep 2026), FIIs 7.71% (Sep 2026), DIIs 18.86% (Sep 2026), Government 0.00% (Sep 2026), Public 15.95% (Sep 2026).

COHANCE quarterly results (₹ Cr.)
Category	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	594.43	653.35	768.57	483.58	497.79	481.58	567.55	359.89
Expenses	390.91	420.60	545.80	379.38	366.93	378.80	450.98	333.40
Operating Profit	203.52	232.75	222.77	104.20	130.86	102.78	116.57	26.49
OPM %	34.24%	35.62%	28.98%	21.55%	26.29%	21.34%	20.54%	7.36%
Other Income	15.76	21.48	-7.59	5.00	26.30	1.26	-17.30	12.16
Interest	9.42	10.08	7.00	6.80	5.24	5.25	5.17	2.12
Depreciation	34.56	38.09	42.58	31.36	31.20	33.36	37.66	34.32
Profit before tax	175.30	206.06	165.60	71.04	120.72	65.43	56.44	2.21
Tax %	20.65%	25.33%	25.86%	26.00%	21.89%	27.72%	38.77%	36.20%
Net Profit	139.10	153.86	122.77	52.57	94.29	47.29	34.56	1.41
EPS in Rs	5.46	6.04	4.82	1.37	2.46	1.24	0.90	0.04
Raw PDF	—	—	—	—	—	—	—	—

COHANCE profit and loss (₹ Cr.)
Category	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	834	1,010	1,320	1,330	1,051	2,504	2,030	1,907
Expenses	449	567	738	739	645	1,720	1,576	1,530
Operating Profit	385	443	582	591	406	784	454	377
OPM %	46%	44%	44%	44%	39%	31%	22%	20%
Other Income	18	14	188	45	57	49	15	22
Interest	22	12	9	13	7	37	22	18
Depreciation	24	32	39	43	55	147	134	137
Profit before tax	358	414	722	579	400	650	314	245
Tax %	24%	25%	23%	25%	26%	24%	27%	—
Net Profit	270	309	558	433	296	491	229	178
EPS in Rs	10.61	12.12	21.92	16.99	11.65	19.29	5.98	4.64
Dividend Payout %	24%	16%	23%	35%	-0%	-0%	-0%	—

COHANCE balance sheet (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	-0.00	13	25	25	25	25	25	38
Reserves	578	770	1,040	1,495	1,724	2,003	4,242	4,442
Borrowings	83	186	143	97	70	65	306	146
Other Liabilities	123	142	151	187	139	121	464	487
Total Liabilities	783	1,111	1,359	1,805	1,958	2,214	5,037	5,113
Fixed Assets	271	357	441	534	512	670	2,079	2,288
CWIP	111	102	96	30	165	179	333	146
Investments	7	276	426	600	710	893	1,117	1,187
Other Assets	394	376	395	641	571	473	1,509	1,493
Total Assets	783	1,111	1,359	1,805	1,958	2,214	5,037	5,113

COHANCE cash flows (₹ Cr.)
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from Operating Activity	50	359	330	270	493	376	686	390
Cash from Investing Activity	-65	-367	-258	-90	-237	-362	-455	-204
Cash from Financing Activity	26	9	-77	-156	-243	-40	-310	-203
Net Cash Flow	11	1	-4	23	13	-26	-79	-18
Free Cash Flow	-6	256	219	195	348	324	386	237
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit	49%	116%	99%	72%	108%	119%	110%	100%

COHANCE shareholding pattern (%)
Category	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026	Sep 2026
Promoters	50.10%	50.10%	66.41%	57.49%	57.49%	57.49%	57.49%	57.48%
FIIs	10.84%	11.05%	7.23%	6.51%	6.01%	5.59%	6.50%	7.71%
DIIs	16.67%	16.60%	11.40%	20.81%	21.57%	21.79%	20.09%	18.86%
Government	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.01%	0.00%
Public	22.37%	22.24%	14.95%	15.16%	14.91%	15.11%	15.92%	15.95%
No. of Shareholders	84,210	86,325	80,910	75,284	81,877	85,230	99,149	93,846

COHANCE key ratios
Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	142	51	37	65	30	46	106	115
Inventory Days	556	278	243	259	284	268	205	302
Days Payable	190	113	100	97	61	49	117	145
Cash Conversion Cycle	509	217	180	228	253	265	195	272
Working Capital Days	205	64	56	107	99	108	121	159
ROCE %	—	46%	39%	50%	34%	21%	21%	8%

COHANCEUpdated 20 Oct 2026, 5:17

Cohance Lifesciences Ltd

COHANCEUpdated 20 Oct 2026, 5:17

Market Cap

₹17,511Cr.

Current Price

₹458

High / Low

₹918/267

Stock P/E

91.6

ROE5.70%

ROCE7.91%

Book Value₹117

Face Value₹1.00

Dividend Yield0.00%

About

Quarterly results

Last reported quarters₹ Cr.

Quarter	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Jun 2023	344.03	1.15	174.15	10.06	11.15	167.64	25.86	124.29	4.88
Sep 2023	224.62	0.5	127.27	14.2	10.48	100.57	25.69	74.73	2.94
Dec 2023	212.82	2.15	143.76	13.97	11.38	69.5	24.66	52.36	2.06
Mar 2024	252.93	2.3	179.6	17.06	17.25	70.84	24.87	53.22	2.09
Jun 2024	488.08	10.2	362.91	19.41	31.28	103.1	26.82	75.45	2.96
Sep 2024	594.43	9.42	390.91	15.76	34.56	175.3	20.65	139.1	5.46
Dec 2024	653.35	10.08	420.6	21.48	38.09	206.06	25.33	153.86	6.04
Mar 2025	768.57	7	545.8	-7.59	42.58	165.6	25.86	122.77	4.82
Jun 2025	483.58	6.8	379.38	5	31.36	71.04	26	52.57	1.37
Sep 2025	497.79	5.24	366.93	26.3	31.2	120.72	21.89	94.29	2.46
Dec 2025	481.58	5.25	378.8	1.26	33.36	65.43	27.72	47.29	1.24
Mar 2026	567.55	5.17	450.98	-17.3	37.66	56.44	38.77	34.56	0.9
Jun 2026	359.89	2.12	333.4	12.16	34.32	2.21	36.2	1.41	0.04

Profit & loss

Annual statement₹ Cr.

Year	Sales	Interest	Expenses	Other Income	Depreciation	Profit Before Tax	Tax	Net Profit	EPS (₹)
Mar 2019 5m	378	3	206	1	12	158	31	109	—
Mar 2020	834	22	449	18	24	358	24	270	10.61
Mar 2021	1010	12	567	14	32	414	25	309	12.12
Mar 2022	1320	9	738	188	39	722	23	558	21.92
Mar 2023	1330	13	739	45	43	579	25	433	16.99
Mar 2024	1051	7	645	57	55	400	26	296	11.65
Mar 2025	2504	37	1720	49	147	650	24	491	19.29
Mar 2026	2030	22	1576	15	134	314	27	229	5.98
TTM	1907	18	1530	22	137	245	—	178	4.64

Shareholding pattern

As of Sep 2026%

Holder	Share
Promoters	57.48%
FIIs	7.71%
DIIs	18.86%
Public	15.95%

Shareholding trend

Ownership over time%

Quarter	Promoters	FIIs	DIIs	Government	Public
Dec 2023	60%	10.14%	15.94%	0.01%	13.93%
Mar 2024	50.1%	9.54%	17.24%	0.01%	23.11%
Jun 2024	50.1%	9.8%	17.42%	0.01%	22.67%
Sep 2024	50.1%	10.7%	16.95%	0.01%	22.26%
Dec 2024	50.1%	10.84%	16.67%	0.01%	22.37%
Mar 2025	50.1%	11.05%	16.6%	0.01%	22.24%
Jun 2025	66.41%	7.23%	11.4%	0.01%	14.95%
Sep 2025	57.49%	6.51%	20.81%	0.01%	15.16%
Dec 2025	57.49%	6.01%	21.57%	0.01%	14.91%
Mar 2026	57.49%	5.59%	21.79%	0.01%	15.11%
Jun 2026	57.49%	6.5%	20.09%	0.01%	15.92%
Sep 2026	57.48%	7.71%	18.86%	0%	15.95%

Balance sheet

Assets & liabilities₹ Cr.

Period	Equity Capital	Reserves	Borrowings	Other Liabilities	Total Liabilities	Fixed Assets	CWIP	Investments	Other Assets	Total Assets
Mar 2019	0	578	83	123	783	271	111	7	394	783
Mar 2020	13	770	186	142	1111	357	102	276	376	1111
Mar 2021	25	1040	143	151	1359	441	96	426	395	1359
Mar 2022	25	1495	97	187	1805	534	30	600	641	1805
Mar 2023	25	1724	70	139	1958	512	165	710	571	1958
Mar 2024	25	2003	65	121	2214	670	179	893	473	2214
Mar 2025	25	4242	306	464	5037	2079	333	1117	1509	5037
Mar 2026	38	4442	146	487	5113	2288	146	1187	1493	5113

Cash flows

Operating, investing & financing₹ Cr.

Period	Operating	Investing	Financing	Net cash flow
Mar 2019	50	-65	26	11
Mar 2020	359	-367	9	1
Mar 2021	330	-258	-77	-4
Mar 2022	270	-90	-156	23
Mar 2023	493	-237	-243	13
Mar 2024	376	-362	-40	-26
Mar 2025	686	-455	-310	-79
Mar 2026	390	-204	-203	-18

Key ratios

Historical financial ratios

Category	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	142	51	37	65	30	46	106	115
Inventory Days	556	278	243	259	284	268	205	302
Days Payable	190	113	100	97	61	49	117	145
Cash Conversion Cycle	509	217	180	228	253	265	195	272
Working Capital Days	205	64	56	107	99	108	121	159
ROCE %	—	46%	39%	50%	34%	21%	21%	8%

Frequently asked questions

Quick answers about this company's financials on Fincrux

What is the market cap of COHANCE LIFESCIENCES LTD (COHANCE)?

The reported market capitalisation for COHANCE LIFESCIENCES LTD (COHANCE) is ₹17,511Cr. on Fincrux. Figures may update with market data and filings.

What is the current share price of COHANCE?

The current price shown for COHANCE LIFESCIENCES LTD (COHANCE) on Fincrux is ₹458 with a 52-week high/low of ₹918/267.

What is the P/E ratio of COHANCE LIFESCIENCES LTD (COHANCE)?

The stock P/E for COHANCE LIFESCIENCES LTD (COHANCE) is 91.6 on Fincrux, with ROE at 5.70% and ROCE at 7.91%.

What were COHANCE latest quarterly results?

For Jun 2026, COHANCE LIFESCIENCES LTD (COHANCE) reported sales ₹359.89 Cr and net profit ₹1.41 Cr (figures in ₹ crore unless noted).

What are COHANCE annual sales and net profit?

For TTM, COHANCE LIFESCIENCES LTD (COHANCE) shows sales of ₹1,907 Cr and net profit of ₹178 Cr on the Fincrux profit & loss statement.

Who owns COHANCE LIFESCIENCES LTD (COHANCE)?

Latest shareholding for COHANCE LIFESCIENCES LTD (COHANCE) on Fincrux: Promoters 57.48% (Sep 2026), FIIs 7.71% (Sep 2026), DIIs 18.86% (Sep 2026), Government 0.00% (Sep 2026), Public 15.95% (Sep 2026).

Where can I find COHANCE LIFESCIENCES LTD (COHANCE) financials?

COHANCE LIFESCIENCES LTD (COHANCE) financials on Fincrux include quarterly results, profit and loss, cash flow, balance sheet, key ratios, and shareholding patterns for NSE/BSE research.

Does Fincrux show COHANCE balance sheet and cash flow?

Yes. The COHANCE LIFESCIENCES LTD (COHANCE) page on Fincrux includes balance sheet, cash flow statements, historical ratios, and ownership trends alongside quarterly and annual results.

Figures in ₹ crore unless noted. Data sourced for research and may lag filings.

Last updated 20 October 2026 at 5:17